sodium ascorbate | 1184919-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢呋喃
• 英文名称: sodium ascorbate
• 英文别名: NaAsc；sodium 2-(1,2-dihydroxyethyl)-4-hydroxy-5-oxo-2,5-dihydro-furan-3-olate；Na-ascorbate；sodium;2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2H-furan-4-olate
• CAS: 1184919-96-7
• 化学式: C₆H₇O₆*Na
• 分子量: 198.108
• InChiKey: PPASLZSBLFJQEF-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -5.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  苯甲醛-α-d1 、 sodium ascorbate 生成 sodium;2-(2-deuterio-2-phenyl-1,3-dioxolan-4-yl)-4-hydroxy-5-oxo-2H-furan-3-olate
  参考文献：
  名称：

  BORRETZEN, BERAT;LARSEN, ROLF O.;PETTERSEN, ERIK O.;DORNISH, JOHN M.;OFTE+

  摘要：

  DOI：
• 作为试剂：
  描述：

  4-(3-azidopropyl)-3-chloro-5-(8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-4-(3-(prop-2-yn-1-yl)piperidin-1-yl)pyrido[4,3-d]pyrimidin-7-yl)phenol 在 sodium ascorbate 作用下， 以52 %的产率得到15-chloro-31-fluoro-4-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1,3,5,9,20,21,22-heptazahexacyclo[23.3.1.16,10.120,23.02,7.011,16]hentriaconta-2,4,6(31),7,9,11(16),12,14,21,23(30)-decaen-13-ol
  参考文献：
  名称：

  PYRIDOPYRIMIDINE KRAS INHIBITORS

  摘要：

  This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a), (I-aa), (I-b), (I-bb), (I-c), (I-cc), (I-d), (I-dd), (I-e), (I-ee), (I-f), (I-g), or (I-h)), Formula (II) (e.g., (II-c), (II-cc), (II-d), (II-dd), (II-e), (II-ee), (II-f), (II-g), or (II-h)), or Formula (Aa)), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein. In some embodiments, the KRas protein has a dysregulation (e.g., the KRas protein is mutated or amplified). These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and/or sustained (e.g., excessive) KRas activation, for example, KRas activation associated with a mutant KRas protein, contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.

  公开号：

  WO2024040131A1

文献信息

• [EN] SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] ACTIVATEURS SOLUBLES DE GUANYLATE CYCLASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015088885A1

  公开（公告）日：2015-06-18

  A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (" cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

  公式I的化合物或其药学上可接受的盐，能够调节体内环鸟苷酸单磷酸（"cGMP"）的产生，并且通常适用于治疗和预防与紊乱的cGMP平衡相关的疾病。此外，本发明还涉及制备公式I的化合物或其药学上可接受的盐的方法，用于治疗和预防上述疾病，并为此目的制备药物，以及包含公式I的化合物或其药学上可接受的盐的药物制剂。
• ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20170275260A1

  公开（公告）日：2017-09-28

  The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

  本公开涉及公式I的化合物，这些化合物可用作α7 nAChR的调节剂，包含这些化合物的组合物，以及利用这些化合物预防、治疗或改善疾病，特别是中枢神经系统疾病，如阿尔茨海默病、帕金森病和精神分裂症，以及L-多巴引起的运动障碍和炎症。
• SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150148327A1

  公开（公告）日：2015-05-28

  The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R cy , C y , and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了以下公式（I）的某些取代吡啶或其药学上可接受的盐，其中R1，R2，R3，R4，Rcy，Cy和t如本文所定义。 本发明还提供了包含这种化合物的制药组合物，并且提供了使用这些化合物治疗由脾酪氨酸激酶（Syk）激酶介导的疾病或病症的方法。
• Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US09376418B2

  公开（公告）日：2016-06-28

  The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  该发明提供了某些式(I)的取代吡啶或其药学上可接受的盐，其中R1、R2、R3、R4、Rcy、Cy和t的定义如本文所述。该发明还提供了包含这些化合物的药物组合物，并使用这些化合物治疗由脾酪氨酸激酶（Syk）介导的疾病或病状的方法。
• Synthesis and reactions of platinum(IV) complexes with sodium ascorbate
  作者：Malcolm J Arendse、Gordon K Anderson、Raquel N Majola、Nigam P Rath

  DOI：10.1016/s0020-1693(02)01058-7

  日期：2002.11

  The platinum(IV) complexes [PtCl2(OH)(2)((NN)-N-boolean AND)] ((NN)-N-boolean AND=en, N,N-dmen, N,N'-dmen) were prepared by oxidation of [PtCl2((NN)-N-boolean AND)] with hydrogen peroxide. The complexes were characterized by multinuclear NMR and infrared spectroscopy, as well as microanalysis. The reactions of these compounds with sodium ascorbate were monitored spectroscopically. Reduction of the platinum(IV) complexes by sodium ascorbate occurred only slowly. An oxalatoplatinum(IV) complex [Pt(C2O4)Cl(OH)(N(boolean AND)Ndmen)]. H2O was isolated from the reaction of [PtCl2(OH)(2)(N,N-dmen)] and sodium ascorbate and characterized by an X-ray diffraction study. (C) 2002 Elsevier Science B.V. All rights reserved.

表征谱图